The long-range goal of this portion of the PPG is to define the pharmacokinetics of synthetic opioid peptide analogs in late pregnancy using the chronically-catheterized pregnant ewe model.
The specific aims for the initial five years of the project will focus in five areas: 1) to determine the effects of pregnancy on the pharmacokinetics of synthetic opioid peptide analogs; 2) to determine the extent of fetal exposure to synthetic opioid peptide analogs with different physiological characteristics; 3 ) to determine the transplacental and nonplacental clearances of these peptide analogs in mother and fetus; 4) to compare the extent of fetal exposure to opioid peptide analogs after maternal intravenous and epidural administration; and 5) to determine the effects of intravenous and epidural administration of opioid peptide analogs on blood pressure, heart rate, plasma glucose, lactate and cortisol levels in both nonpregnant and pregnant sheep. Maternal and fetal plasma levels of the peptide analogs will be assayed using mass spectrometry in Dr. Desiderio's laboratory. These data will be used to test the first general hypothesis of the PPG, namely that placental transfer of opioid peptide analogs will be determined by their physicochemical characteristics, and their transfer will be more limited compared to opiate alkaloids. The proposed studies will provide new and clinically-relevant information on the effects of pregnancy and route of administration of peptide pharmacokinetics. In addition, these studies will contribute to our understanding of the physicochemical characteristics which favor the transfer of peptides across the placenta, dura and blood-brain barrier. Finally, the plasma concentration-response data will provide new information on the effects of pregnancy on opioid actions, as well as aid in dose selection for the maternal-fetal pharmacodynamic studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA008924-03S1
Application #
2779912
Study Section
Project Start
Project End
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
Szeto, H H; Birk, A V (2014) Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther 96:672-83
Shimoyama, Megumi; Schiller, Peter W; Shimoyama, Naohito et al. (2012) Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), a multifunctional opioid peptide, compared to morphine in a rat model of neuropathic pain. Chem Biol Drug Des 80:771-4
Han, Zhaosheng; Varadharaj, Saradhadevi; Giedt, Randy J et al. (2009) Mitochondria-derived reactive oxygen species mediate heme oxygenase-1 expression in sheared endothelial cells. J Pharmacol Exp Ther 329:94-101
Yang, Lichuan; Zhao, Kesheng; Calingasan, Noel Y et al. (2009) Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal 11:2095-104
Shimoyama, Megumi; Szeto, Hazel H; Schiller, Peter W et al. (2009) Differential analgesic effects of a mu-opioid peptide, [Dmt(1)]DALDA, and morphine. Pharmacology 83:33-7
Fichna, Jakub; do-Rego, Jean-Claude; Chung, Nga N et al. (2008) [Dmt1, d-1-Nal3]morphiceptin, a novel opioid peptide analog with high analgesic activity. Peptides 29:633-8
Szeto, Hazel H (2008) Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci 1147:112-21
Fichna, Jakub; do-Rego, Jean-Claude; Janecki, Tomasz et al. (2008) Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett 18:1350-3
Mizuguchi, Yasunori; Chen, Jie; Seshan, Surya V et al. (2008) A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol 295:F1545-53
Szeto, Hazel H (2008) Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal 10:601-19

Showing the most recent 10 out of 56 publications